Use of anti-PD-1 antibodies in combination with anti-CD30 antibodies in the treatment of lymphoma

摘要

The present application discloses the use of two PD-1 blocking antibodies, nobiludip or fembrolizumab, which inhibit tumor immunity evasion in patients with relapsed or refractory Hodgkin''s lymphoma, with an anti-CD30 antibody, such as brenuximab And a method of treating Hodgkin''s lymphoma or non-hodgkin lymphoma in a subject.